Compare SINT & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SINT | NXL |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 10.2M |
| IPO Year | 2007 | N/A |
| Metric | SINT | NXL |
|---|---|---|
| Price | $1.92 | $0.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | 46.2K | ★ 227.0K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.45 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,018,000.00 | N/A |
| Revenue This Year | $30.26 | $15.52 |
| Revenue Next Year | $413.20 | $100.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.85 | $0.31 |
| 52 Week High | $6.78 | $2.00 |
| Indicator | SINT | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 40.43 | 38.74 |
| Support Level | $1.93 | $0.35 |
| Resistance Level | $2.98 | $0.46 |
| Average True Range (ATR) | 0.15 | 0.04 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 27.59 | 12.46 |
SINTX Technologies Inc is an advance ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. It provides biomedical solutions for medical devices specializing in silicon nitride (Si3N4) for musculoskeletal and antipathogenic applications. It also manufactures silicon nitride parts for customers in the electrical, aerospace, and other industrial sectors. The company is a globalised leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans. The Company operates as one operating segment.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.